Followers | 9 |
Posts | 750 |
Boards Moderated | 0 |
Alias Born | 10/19/2008 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, December 23, 2015 10:04:29 AM
The Florey Institute of Neuroscience and Mental Health is one of the world’s leading brain research centers. Florey employs more than 500 staff and educate in excess of 100 post-graduate students each year. Our scientists comprise the largest neuroscience research team in Australia.
Teams work on a range of serious diseases including stroke, epilepsy, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, Huntington’s disease, motor neuron disease, traumatic brain and spinal cord injury, depression, schizophrenia, mental illness and addiction. We are world leaders in imaging technology, stroke rehabilitation and epidemiological studies.
Over the past 10 years research of the brain and its diseases has gained considerable momentum internationally. Many scientific and technological advancements have been made, and much of Florey's work has been center stage. They are a hive of activity with researchers coming from around the globe to work at the Florey.
State and Federal Governments, major philanthropic foundations and many generous private benefactors have recognized the importance of neuroscience as the final frontier in medical research, and they are helping Florey and its partners build two state-of-the-art research facilities, one at the University of Melbourne in Parkville and the other at the Austin Hospital in Heidelberg costing in excess of $200 million.
ISCO could not have picked a better partner to move their Parkinson therapeutics through the human studies to quickly benefit the worlds's population suffering or those that would be going to suffer from Parkinsons.
ISCO continuously marching forward.
Recent ISCO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 08:05:50 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:00:42 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:00:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/08/2023 06:18:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/08/2023 06:17:20 PM
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 09/27/2023 04:27:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2023 12:01:30 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/11/2023 06:20:54 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM